Bridgeway Capital Management, LLC Harrow Health, Inc. Transaction History

Bridgeway Capital Management, LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$8.1 - $16.36 $396,900 - $801,640	-49,000 Reduced 25.39%	144,000 $1.61 Million
Q3 2023 Nov 14, 2023	SELL	$14.03 - $22.08 $61,732 - $97,151	-4,400 Reduced 2.23%	193,000 $2.77 Million
Q2 2023 Aug 14, 2023	SELL	$17.37 - $28.08 $698,274 - $1.13 Million	-40,200 Reduced 16.92%	197,400 $3.76 Million
Q1 2023 May 15, 2023	SELL	$13.84 - $21.46 $463,640 - $718,910	-33,500 Reduced 12.36%	237,600 $5.03 Million
Q4 2022 Feb 14, 2023	SELL	$10.28 - $14.78 $462,600 - $665,100	-45,000 Reduced 14.24%	271,100 $4 Million
Q3 2022 Nov 14, 2022	SELL	$6.57 - $24.88 $24,309 - $92,056	-3,700 Reduced 1.16%	316,100 $3.82 Million
Q2 2022 Aug 15, 2022	BUY	$5.75 - $7.74 $41,400 - $55,728	7,200 Added 2.3%	319,800 $2.33 Million
Q1 2022 May 16, 2022	BUY	$6.77 - $8.66 $351,363 - $449,454	51,900 Added 19.91%	312,600 $2.13 Million
Q4 2021 Feb 14, 2022	SELL	$8.5 - $12.0 $34,102 - $48,144	-4,012 Reduced 1.52%	260,700 $2.25 Million
Q3 2021 Nov 15, 2021	BUY	$6.99 - $10.6 $892,706 - $1.35 Million	127,712 Added 93.22%	264,712 $2.41 Million
Q2 2021 Aug 16, 2021	SELL	$6.68 - $11.07 $614,560 - $1.02 Million	-92,000 Reduced 40.17%	137,000 $1.27 Million
Q1 2021 May 17, 2021	BUY	$6.26 - $11.03 $579,676 - $1.02 Million	92,600 Added 67.89%	229,000 $1.55 Million
Q4 2020 Feb 16, 2021	BUY	$4.76 - $6.93 $649,264 - $945,252	136,400 New	136,400 $936,000
Q2 2019 Aug 14, 2019	SELL	$4.2 - $8.7 $181,020 - $374,969	-43,100 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$2.25 - $6.11 $96,975 - $263,341	43,100 New	43,100 $245,000

177

21.4M

845K

717K

Ticker HROW
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 27,070,000
Market Cap $992M
Description
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company tha...

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridgeway Capital Management, LLC with notifications on news.